VigiBase is aWorld Health Organization's (WHO) global Individual Case Safety Report (ICSR) database that contains ICSRs submitted by the participating member states enrolled under WHO's international drug monitoring programme. It is the single largest drug safety data repository in the world. Since 1978, theUppsala Monitoring Centre (UMC; established inUppsala,Sweden) on behalf of WHO, have been maintaining VigiBase.[1]
Vigibase is used to obtain the information about a safety profile of a medicinal product. These data are used by pharmaceutical industries, academic institutions and regulatory authorities for statistical signal detection, updating periodic reports, ICSR comparisons with company databases and studying the reporting patterns.[2]The data (pre-dominantly post-marketing serious and non-serious cases) is collected from each of its 110 member states which currently comprises to over 10 million ICSRs (October 2014).[2] About a hundred thousand ICSRs are added each year.
 | This articleis inlist format but may read better asprose. You can help byconverting this article, if appropriate.Editing help is available.(April 2023) |
It is mandatory for all the participating countries (125 members states and 28 associate members) to submit ICSRs to UMC via its appointed national centre based in the respective member states, authorized by itscompetent authority or thehealth authority itself. These reports are usually sent to the respective national centre by marketing authorization holders, health care professionals (HCP), consumers or any regional centre. Most of participating member have a well established system for collection of ICSRs.[3]These submissions are inICH E2B format and are reported more than once a month or at least every quarter. For some member states that lack an E2B compatible database for ICSR management, UMC in collaboration withSwissmedic has developedVigiFlow, a web-based ICSR management system. VigiFlow functions as a national ICSR database management system and analysis tool, through which cases are sent to UMC.[4]
With primary objective of identify the earliest possiblepharmacovigilance signals, the usage of VigiBase is permitted and accessed by the following authorities:[5]
VigiBase is arelational database management system (RDMS) which is compatible with ODBC (open database connectivity) and usesSQL for the database communication. The RDMS can be accessed through client server applications, ODBC, and Internet applications. Apart from data management, the VigiBase system includes an automated signal detection process using advanced data mining tools (VigiMine- a Bayesian Confidence Propagation Neural Network (BCPNN) data mining tool).[1] VigiBase further includes a WHO Drug Dictionaries (WHO-DD and -DDE), and medical terminology dictionary such as WHO Adverse Reaction Terminology (WHO-ART),International Classification of Diseases (ICD), and theMedical Dictionary for Regulatory Activities (MedDRA).[6]
Type of reports: Most preferred data includes post-marketing spontaneous serious and non-serious cases ICSRs. Case reports from studies,clinical trials or special monitoring and literature are sometimes included, but are flagged.[4]Type of medicine: Database includes ICSRs on ordinaryallopathic medicines, traditional medicines (herbals), biologics,vaccines andmedical devices. In addition, ICSRs on medication errors, therapeutic failure and counterfeit/substandard medicines are also considered.[4]